bluebird bio Inc.’s recent filing unveils that its President and CEO Obenshain Andrew unloaded Company’s shares for reported $59956.0 on Aug 10. In the deal valued at $3.54 per share,16,929 shares were sold. As a result of this transaction, Obenshain Andrew now holds 291,941 shares worth roughly $ 1.08 million.
Then, Klima Thomas J sold 4,130 shares, generating $14,451 in total proceeds. Upon selling the shares at $3.50, the insider now owns 133,049 shares.
Before that, Leschly Nick sold 4,290 shares. bluebird bio Inc. shares valued at $33,480 were divested by the Director at a price of $7.80 per share. As a result of the transaction, Leschly Nick now holds 280,149 shares, worth roughly $1.04 million.
BofA Securities upgraded its bluebird bio Inc. [BLUE] rating to a Buy from a a Neutral in a research note published on Tuesday, July 19, 2023; the price target was increased to $10 from $6. PT values the company’s stock at a premium of 62.9 to its Tuesday closing price.
Price Performance Review of BLUE
On Tuesday, bluebird bio Inc. [NASDAQ:BLUE] saw its stock fall -4.87% to $3.71. On the same session, the stock had its day’s lowest price of $3.685, but rose to a high of $3.90. Over the last five days, the stock has lost -5.12%. bluebird bio Inc. shares have fallen nearly -46.39% since the year began. Nevertheless, the stocks have fallen -43.36% over the past one year. While a 52-week high of $8.58 was reached on 01/13/23, a 52-week low of $2.78 was recorded on 04/12/23. SMA at 50 days reached $3.58, while 200 days put it at $4.88. A total of 2.66 million shares were traded, compared to the trading of 2.02 million shares in the previous session.
Levels Of Support And Resistance For BLUE Stock
The 24-hour chart illustrates a support level at 3.63, which if violated will result in even more drops to 3.55. On the upside, there is a resistance level at 3.85. A further resistance level may holdings at 3.98. The Relative Strength Index (RSI) on the 14-day chart is 51.58, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.15, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 40.81%. Stochastics %K at 77.47% indicates the stock is a holding.
How much short interest is there in bluebird bio Inc.?
A steep rise in short interest was recorded in bluebird bio Inc. stocks on Aug 14, 2023, growing by 1.09 million shares to a total of 26.45 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 25.36 million shares. There was a rise of 4.12%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 27.93% of the overall stock float, the days-to-cover ratio (short ratio) rose to 4.65.
bluebird bio Inc. [BLUE] – Who Are The Largest Shareholders?
In filings from SSgA Funds Management, Inc., it is revealed that the company now owns 16,358,130 shares, or roughly 15.37% of the outstanding BLUE shares. In other words, the investor’s shares have fallen by -1,407,416 from its previous 13-F filing of 17765546.0. Additionally, BlackRock Fund Advisors increased 1.31% of its stake after which the total value it holdings stand at $30,427,196, while Tang Capital Management LLC reduced -25.30% of its stake to hold $29.01 million in the firm. Over the last quarter, PFM Health Sciences LP purchased 2,699,339 shares of bluebird bio Inc., while The Vanguard Group, Inc. bought 165,621 shares. At present, Granahan Investment Management, L is holding 4,856,322 shares valued at $19.09 million. Pictet Asset Management SA owned 4,666,813 shares of the company at the time of its most recent 13F filing, worth $18.34 million.
According to FactSet, bluebird bio Inc.’s share price will average $7.36 in the next year, based on opinions of analysts polled by the firm. This is up nearly 105.13 percent from its previous closing price of $3.90. Analysts expect bluebird bio Inc. stock to reach the higher price of $11.00, while the lowest price estimate is $3.00. However, 13 analysts have rated BLUE stock as a Hold in their predictions for 2023.